APOE genotype-dependent differences in very low-density lipoprotein (VLDL) secretion, hepatic clearance of circulating lipids and immune cell activation may at least contribute to the increased risk of steatosis and steatohepatitis in non-APOE epsilon 4 carriers. Here, APOE is linked to steatosis.